Author:
Lopez-Saavedra Javier,Abad-Santos Francisco
Reference31 articles.
1. American Psychological Association (Ed.). (2019). Clinical practice guideline for the treatment of depression across three age cohorts. https://www.apa.org/depression-guideline/guideline.pdf (accessed 29 October 2022).
2. Anderson, H. D., Thant, T. M., Kao, D. P., Crooks, K. R., Mendola, N. D., & Aquilante, C. L. (2022). Pharmacogenetic testing among patients with depression in a US managed care population. Clin. Transl. Sci., 15(7), 1644-1653doi:https://doi.org/10.1111/cts.13279.
3. The increasing economic burden with additional steps of pharmacotherapy in major depressive disorder;Arnaud;PharmacoEconomics,2021
4. Clinical utility of pharmacogenetics in a psychiatric and primary care population;Bohlen;Pharmacogenomics J.,2022
5. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants;Bousman;Clin. Pharmacol. Ther.,2023